High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 3, 2012, Pages 246-256

  Cerignoli, Fabio ^a,b   Charlot, David ^a   Whittaker, Ross ^b   Ingermanson, Randy ^b   Gehalot, Piyush ^b   Savchenko, Alex ^a   Gallacher, David J ^c   Towart, Rob ^c   Price, Jeffrey H ^a,b   McDonough, Patrick M ^b   Mercola, Mark ^a  

^a BURNHAM INSTITUTE   (United States)

^b VALA SCIENCES INC   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Arrhythmogenicity; Calcium transient; Cardiomyocyte; Cardiotoxicity; High content; Pharmacology

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ACETYLSALICYLIC ACID; CALCIUM; CALCIUM CHANNEL; CISAPRIDE; FLECAINIDE; LEMAKALIM; MOSAPRIDE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SOTALOL; VERAPAMIL;

ARRHYTHMOGENESIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CARDIOTOXICITY; CHANNEL GATING; ELECTRODE; ELECTROSTIMULATION; EMBRYO; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE CYTOMETRY; MUSCLE FIBER CONTRACTION; NEWBORN; NONHUMAN; PATCH CLAMP; PLURIPOTENT STEM CELL; RAT; RISK ASSESSMENT; STEM CELL; TIME SERIES ANALYSIS;

EID: 84870715347     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.08.167     Document Type: Article

References (58)

1. Antzelevitch, C. (2004). Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem? Journal of Electrocardiology, 37, 15-24.
2. Balasubramaniam, R., Chawla, S., Grace, A. A., & Huang, C. L. H. (2005). Caffeine-induced arrhythmias in murine hearts parallel changes in cellular Ca2+ homeostasis. American Journal of Physiology - Heart and Circulatory Physiology, 289, 1584-1593.
3. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature, 415, 198-205.
4. Bode, G., & Olejniczak, K. (2002). ICH topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticals. Fundamental & Clinical Pharmacology, 16, 105-118.
5. Bootman, M. D., Fearnley, C., Smyrnias, I., MacDonald, F., & Roderick, H. L. (2009). An update on nuclear calcium signalling. Journal of Cell Science, 122, 2337-2350.
6. Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., & Mummery, C. L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research, 4, 107-116.
7. Bravo-Zanoguera, M., Massenbach, B., Kellner, A., & Price, J. (1998). High-performance autofocus circuit for biological microscopy. The Review of Scientific Instruments, 69, 3966-3977.
8. Cavero, I., & Crumb, W. (2005). ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opinion on Drug Safety, 4, 509-530.
9. Choi, B. R., Burton, F., & Salama, G. (2002). Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. The Journal of Physiology, 543, 615-631.
10. Clapham, D. E. (2007). Calcium signaling. Cell, 131, 1047-1058.
11. Denning, C., & Anderson, D. (2008). Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discovery Today: Therapeutic Strategies, 5, 223-232.
12. Fermini, B., & Fossa, A. A. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews. Drug Discovery, 2, 439-447.
13. Fernandez-Velasco, M., Rueda, A., Rizzi, N., Benitah, J. -P., Colombi, B., Napolitano, C., et al. (2009). Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circulation Research, 104, 201-209.
14. Fossa, A. A., Wisialowski, T., Wolfgang, E., Wang, E., Avery, M., Raunig, D. L., et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. European Journal of Pharmacology, 486, 209-221.
15. Guth, B. D. (2007). Preclinical cardiovascular risk assessment in modern drug development. Toxicological Sciences, 97, 4-20.
16. Gwathmey, J. K., Tsaioun, K., & Hajjar, R. J. (2009). Cardionomics: A new integrative approach for screening cardiotoxicity of drug candidates. Expert Opinion on Drug Metabolism & Toxicology, 5, 647-660.
17. Hansen, R. S., Diness, T. G., Christ, T., Demnitz, J., Ravens, U., Olesen, S. r. -P., et al. (2006). Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Molecular Pharmacology, 69, 266-277.
18. Heynen, S., Gough, D. A., & Price, J. H. (1997). Optically stabilized mercury vapor short arc lamp as UV-light source for microscopy. SPIE Proc. Optical Diagnostics of Biological Fluids and Advanced Techniques Analytical Cytology, 2982. (pp. 430-434).
19. Hoffmann, P., & Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. Journal of Pharmacological and Toxicological Methods, 53, 87-105.
20. Hondeghem, L. M. (2008). Use and abuse of QT and TRIaD in cardiac safety research: Importance of study design and conduct. European Journal of Pharmacology, 584, 1-9.
21. Houjou, S., Iizuka, K., Dobashi, K., & Nakazawa, T. (1996). Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea. The European Respiratory Journal, 9, 2050-2056.
22. Hove-Madsen, L., Llach, A., Molina, C. E., Prat-Vidal, C., Farré, J., Roura, S., et al. (2006). The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. European Journal of Pharmacology, 553, 215-221.
23. Humbert, J. -P., Matter, N., Artault, J. -C., Köppler, P., & Malviya, A. N. (1996). Inositol 1,4,5-trisphosphate receptor is located to the inner nuclear membrane vindicating regulation of nuclear calcium signaling by inositol 1,4,5-trisphosphate. The Journal of Biological Chemistry, 271, 478-485.
24. Kagan, A., & McDonald, T. V. (2005). Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3. Novartis Foundation Symposium, 266, 75-89.
25. Kahaly, G. J., & Dillmann, W. H. (2005). Thyroid hormone action in the heart. Endocrine Reviews, 26, 704-728.
26. Kii, Y., & Ito, T. (2002). Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block. Pharmacology & Toxicology, 90, 246-253.
27. Kita-Matsuo, H., Barcova, M., Prigozhina, N., Salomonis, N., Wei, K., Jacot, J. G., et al. (2009). Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PloS one, 4, e5046.
28. Klein, I., & Danzi, S. (2007). Thyroid disease and the heart. Circulation, 116, 1725-1735.
29. Komukai, K., O-Uchi, J., Morimoto, S., Kawai, M., Hongo, K., Yoshimura, M., et al. (2010). Role of Ca2+/calmodulin-dependent protein kinase II in the regulation of the cardiac L-type Ca2+ current during endothelin-1 stimulation. American Journal of Physiology - Heart and Circulatory Physiology, 298, 1902-1907.
30. Maeda, A., Honda, M., Kuramochi, T., & Takabatake, T. (1998). Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes. Japanese Circulation Journal, 62, 505-511.
31. Marius, P., Guerra, M. T., Nathanson, M. H., Ehrlich, B. E., & Leite, M. F. (2006). Calcium release from ryanodine receptors in the nucleoplasmic reticulum. Cell Calcium, 39, 65-73.
32. Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F., & Gintant, G. A. (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology, 43, 369-379.
33. Mattheakis, L. C., & Ohler, L. D. (2000). Seeing the light: Calcium imaging in cells for drug discovery. Drug Discovery Today, 5, 15-19.
34. Menna, P., Salvatorelli, E., & Minotti, G. (2008). Cardiotoxicity of antitumor drugs. Chemical Research in Toxicology, 21, 978-989.
35. Milan, D. J., Peterson, T. A., Ruskin, J. N., Peterson, R. T., & MacRae, C. A. (2003). Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation, 107, 1355-1358.
36. Mohammad, S., Zhou, Z., Gong, Q., & January, C. T. (1997). Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. American Journal of Physiology - Heart and Circulatory Physiology, 273, H2534-H2538.
37. Monteith, G. R., & Bird, G. S. J. (2005). Techniques: High-throughput measurement of intracellular Ca2+ back to basics. Trends in Pharmacological Sciences, 26, 218-223.
38. Ogawa, S., Barnett, J. V., Sen, L., Galper, J. B., Smith, T. W., & Marsh, J. D. (1992). Direct contact between sympathetic neurons and rat cardiac myocytes in vitro increases expression of functional calcium channels. The Journal of Clinical Investigation, 89, 1085-1093.
39. Oliva, M., Bravo-Zanoguera, M. E., & Price, J. H. (1999). Filtering out contrast reversals for microscopy autofocus. Applied Optics, 38, 638-646.
40. Olson, R. D., Gambliel, H. A., Vestal, R. E., Shadle, S. E., Charlier, H. A., Jr., & Cusack, B. J. (2005). Doxorubicin cardiac dysfunction: Effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovascular Toxicology, 5, 269-283.
41. Patmore, L., Fraser, S., Mair, D., & Templeton, A. (2000). Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. European Journal of Pharmacology, 406, 449-452.
42. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M., & Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. Journal of Pharmacological and Toxicological Methods, 61, 277-286.
43. Potet, F., Bouyssou, T., Escande, D., & Baró, I. (2001). Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. The Journal of Pharmacology and Experimental Therapeutics, 299, 1007-1012.
44. Qian, J. -Y., & Guo, L. (2010). Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicology in Vitro, 24, 960-972.
45. Ramos, E., & O'Leary, M. E. (2004). State-dependent trapping of flecainide in the cardiac sodium channel. The Journal of Physiology, 560, 37-49.
46. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32-45.
47. Schubert, W., Bonnekoh, B., Pommer, A. J., Philipsen, L., Bockelmann, R., Malykh, Y., et al. (2006). Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nature Biotechnology, 24, 1270-1278.
48. Snyders, D. J., & Chaudhary, A. (1996). High affinity open channel block by dofetilide of HERG expressed in a human cell line. Molecular Pharmacology, 49, 949-955.
49. Solem, L. E., Henry, T. R., & Wallace, K. B. (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicology and Applied Pharmacology, 129, 214-222.
50. Takahashi, A., Camacho, P., Lechleiter, J. D., & Herman, B. (1999). Measurement of intracellular calcium. Physiological Reviews, 79, 1089-1125.
51. Toga, T., Kohmura, Y., & Kawatsu, R. (2007). The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-gogo-related gene (hERG)-blocking activities. Journal of Pharmacological Sciences, 105, 207-210.
52. Towart, R., Linders, J. T. M., Hermans, A. N., Rohrbacher, J., van der Linde, H. J., Ercken, M., et al. (2009). Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening? Journal of Pharmacological and Toxicological Methods, 60, 1-10.
53. Valentin, J. -P., Hoffmann, P., De Clerck, F., Hammond, T. G., & Hondeghem, L. (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. Journal of Pharmacological and Toxicological Methods, 49, 171-181.
54. Vincent, L. (1991). Watersheds in digital spaces: An efficient algorithm based on immersion simulations. IEEE Transactions on Pattern Analysis and Machine Intelligence, 13, 583-598.
55. Werdich, A. A., Lima, E. A., Dzhura, I., Singh, M. V., Li, J., Anderson, M. E., et al. (2008). Differential effects of phospholamban and Ca2+/calmodulin-dependent kinase II on [Ca2+]i transients in cardiac myocytes at physiological stimulation frequencies. American Journal of Physiology - Heart and Circulatory Physiology, 294, H2352-H2362.
56. Zahradnik, I., Minarovic, I., & Zahradnikova, A. (2008). Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. The Journal of Pharmacology and Experimental Therapeutics, 324, 977-984.
57. Zahradník, I., Minarovic, I., & Zahradníková, A. (2008). Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. The Journal of Pharmacology and Experimental Therapeutics, 324, 977-984.
58. Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C., & January, C. T. (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circulation Research, 84, 989-998.